rac-1-Stearoyl-glycerin-3-phosphorylcholin | 13655-40-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: rac-1-Stearoyl-glycerin-3-phosphorylcholin
• 英文别名: 1-Stearoyl-glycero-3-phosphorylcholin；1-Stearoyl-sn-glycero-3-phosphocholine, >=99%, powder；2-[hydroxy-(2-hydroxy-3-octadecanoyloxypropoxy)phosphoryl]oxyethyl-trimethylazanium
• CAS: 13655-40-8
• 化学式: C₂₆H₅₅NO₇P
• 分子量: 524.699
• InChiKey: IHNKQIMGVNPMTC-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  35
• 可旋转键数：
  26
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  油酰氯 、 rac-1-Stearoyl-glycerin-3-phosphorylcholin 生成 (2-{Hydroxy-[3-octadecanoyloxy-2-((Z)-octadec-9-enoyloxy)-propoxy]-phosphoryloxy}-ethyl)-trimethyl-ammonium
  参考文献：
  名称：

  de Haas,G.H.; van Deenen,L.L.M., Tetrahedron Letters, 1960, # 22, p. 7 - 9

  摘要：

  DOI：
• 作为产物：
  描述：

  γ-Oleoyl-L-α-lysolecithin 在 铂 氢气 作用下， 以 乙醇 为溶剂， 生成 rac-1-Stearoyl-glycerin-3-phosphorylcholin
  参考文献：
  名称：

  de Haas,G.H.; van Deenen,L.L.M., Tetrahedron Letters, 1960, # 22, p. 7 - 9

  摘要：

  DOI：

文献信息

• IMPROVED PROMOTERS AND COMPOSITIONS
  申请人：Oxford University Innovation Limited

  公开号：EP3423579A1

  公开（公告）日：2019-01-09
• PHOSPHOLIPID DERIVATIVES AND THEIR USE AS MEDICAMENTS
  申请人：Ustav molekularni genetiky AV CR, v.v.i.

  公开号：EP3606534B1

  公开（公告）日：2021-05-12
• BIOMARKERS USEFUL FOR DIAGNOSING PROSTATE CANCER, AND METHODS THEREOF
  申请人：Ritchie Shawn

  公开号：US20090127454A1

  公开（公告）日：2009-05-21

  The present invention describes a method for predicting a health-state indicative of the presence of prostate cancer. The method measures the intensities of specific small biochemicals, called metabolites, in a blood sample from a patient with an undetermined health-state, and compares these intensities to the intensities observed in a population of healthy individuals and/or to the intensities previously observed in a population of confirmed prostate cancer-positive individuals. The method enables a practitioner to determine the probability that a screened patient is positive for prostate cancer.
• PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS
  申请人：GLYCOREGIMMUNE, INC.

  公开号：US20160158258A1

  公开（公告）日：2016-06-09

  In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.
• COMPOUNDS AND METHODS FOR MANAGING CANCER THROUGH IMMUNE SYSTEM
  申请人：AKAMARA THERAPEUTICS, INC.

  公开号：US20220168261A1

  公开（公告）日：2022-06-02

  The present disclosure relates to methods of managing cancer by modulating/inhibiting cap methyltransferase enzyme. The modulation/inhibition is carried out by pharmacological or biological inhibitors, including but not limited to compounds of formula (VIII) or Compound A or A-1. Thus, the present disclosure relates to such inhibitors including compounds of formula (VIII) and their use for management of cancer. In some aspects, the compound of formula (VIII) is Compound 1. The present disclosure also relates to methods of activating B cells or T cells via modulation of cap methyltransferases. The present disclosure also relates to methods of managing cancer with a molecule or biologic that generates unmethylated RNA. The generation of unmethylated RNA activates B cells and presents the RNA to B-cell receptor (BCR). The present disclosure therefore also relates to management of cancer by activating B cells and then adoptively transferring the B cells to exert an anticancer effect.